Literature DB >> 25998949

Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury.

Seung-Hyun Kim1,2, Katy Saide1, John Farrell1, Lee Faulkner1, Arun Tailor1, Monday Ogese1, Ann K Daly3, Munir Pirmohamed1,4, B Kevin Park1, Dean J Naisbitt1.   

Abstract

UNLABELLED: Drug-induced liver injury (DILI) frequently has a delayed onset with several human leukocyte antigen (HLA) genotypes affecting susceptibility, indicating a potential role for the adaptive immune system in the disease. The aim of this study was to investigate whether drug-responsive T lymphocytes are detectable in patients who developed DILI with the combination, antimicrobial amoxicillin-clavulanate. Lymphocytes from 6 of 7 patients were found to proliferate and/or secrete interferon-gamma (IFN-γ) when cultured with amoxicillin and/or clavulanic acid. Amoxicillin (n = 105) and clavulanic acid (n = 16) responsive CD4(+) and CD8(+) T-cell clones expressing CCR, chemokine (C-C motif) receptor 4, CCR9, and chemokine (C-X-C motif) receptor 3 were generated from patients with and without HLA risk alleles; no cross-reactivity was observed between the two drug antigens. Amoxicillin clones were found to secrete a heterogeneous panel of mediators, including IFN-γ, interleukin-22 and cytolytic molecules. In contrast, cytokine secretion by the clavulanic acid clones was more restricted. CD4(+) and CD8(+) clones were major histocompatability complex class II and I restricted, respectively, with the drug antigen being presented to CD4(+) clones in the context of HLA-DR molecules. Several pieces of evidence indicate that the clones were activated by a hapten mechanism: First, professional antigen-presenting cells (APCs) were required for optimal activation; second, pulsing APCs for 4-16 hours activated the clones; and third, inhibition of processing abrogated the proliferative response and cytokine release.
CONCLUSION: Both amoxicillin- and clavulanic acid-specific T cells participate in the liver injury that develops in certain patients exposed to amoxicillin-clavulanate.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25998949     DOI: 10.1002/hep.27912

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  17 in total

Review 1.  Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models.

Authors:  Richard J Weaver; Eric A Blomme; Amy E Chadwick; Ian M Copple; Helga H J Gerets; Christopher E Goldring; Andre Guillouzo; Philip G Hewitt; Magnus Ingelman-Sundberg; Klaus Gjervig Jensen; Satu Juhila; Ursula Klingmüller; Gilles Labbe; Michael J Liguori; Cerys A Lovatt; Paul Morgan; Dean J Naisbitt; Raymond H H Pieters; Jan Snoeys; Bob van de Water; Dominic P Williams; B Kevin Park
Journal:  Nat Rev Drug Discov       Date:  2019-11-20       Impact factor: 84.694

Review 2.  Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management.

Authors:  M Mosedale; P B Watkins
Journal:  Clin Pharmacol Ther       Date:  2017-01-11       Impact factor: 6.875

3.  Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response.

Authors:  Jessica Whritenour; Mira Ko; Qing Zong; Jianying Wang; Karrie Tartaro; Patricia Schneider; Ellen Olson; Maria Van Volkenburg; Jose Serrano; Paul Hayashi; Robert Fontana; Naga Chalasani; Herbert L Bonkovsky
Journal:  J Immunotoxicol       Date:  2017-12       Impact factor: 3.000

4.  Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.

Authors:  Paola Nicoletti; Guruprasad P Aithal; Einar S Bjornsson; Raul J Andrade; Ashley Sawle; Marco Arrese; Huiman X Barnhart; Emmanuelle Bondon-Guitton; Paul H Hayashi; Fernando Bessone; Alfonso Carvajal; Ingolf Cascorbi; Elizabeth T Cirulli; Naga Chalasani; Anita Conforti; Sally A Coulthard; Mark J Daly; Christopher P Day; John F Dillon; Robert J Fontana; Jane I Grove; Pär Hallberg; Nelia Hernández; Luisa Ibáñez; Gerd A Kullak-Ublick; Tarja Laitinen; Dominique Larrey; M Isabel Lucena; Anke H Maitland-van der Zee; Jennifer H Martin; Mariam Molokhia; Munir Pirmohamed; Elizabeth E Powell; Shengying Qin; Jose Serrano; Camilla Stephens; Andrew Stolz; Mia Wadelius; Paul B Watkins; Aris Floratos; Yufeng Shen; Matthew R Nelson; Thomas J Urban; Ann K Daly
Journal:  Gastroenterology       Date:  2016-12-30       Impact factor: 22.682

Review 5.  The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions.

Authors:  Patricia T Illing; Anthony W Purcell; James McCluskey
Journal:  Immunogenetics       Date:  2017-07-10       Impact factor: 3.330

6.  Exploration of Biomarkers for Amoxicillin/Clavulanate-Induced Liver Injury: Multi-Omics Approaches.

Authors:  J Lee; S C Ji; B Kim; S Yi; K H Shin; J Y Cho; K S Lim; S H Lee; S H Yoon; J Y Chung; K S Yu; H S Park; S H Kim; I J Jang
Journal:  Clin Transl Sci       Date:  2016-10-26       Impact factor: 4.689

7.  Definition of the Nature and Hapten Threshold of the β-Lactam Antigen Required for T Cell Activation In Vitro and in Patients.

Authors:  Xiaoli Meng; Zaid Al-Attar; Fiazia S Yaseen; Rosalind Jenkins; Caroline Earnshaw; Paul Whitaker; Daniel Peckham; Neil S French; Dean J Naisbitt; B Kevin Park
Journal:  J Immunol       Date:  2017-04-24       Impact factor: 5.422

8.  Beta-lactam-induced immediate hypersensitivity reactions: A genome-wide association study of a deeply phenotyped cohort.

Authors:  Paola Nicoletti; Daniel F Carr; Sarah Barrett; Laurence McEvoy; Peter S Friedmann; Neil H Shear; Matthew R Nelson; Anca M Chiriac; Natalia Blanca-López; José A Cornejo-García; Francesco Gaeta; Alla Nakonechna; Maria J Torres; Cristiano Caruso; Rocco L Valluzzi; Aris Floratos; Yufeng Shen; Rebecca K Pavlos; Elizabeth J Phillips; Pascal Demoly; Antonino Romano; Miguel Blanca; Munir Pirmohamed
Journal:  J Allergy Clin Immunol       Date:  2020-10-13       Impact factor: 10.793

Review 9.  Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?

Authors:  Erin F Barreto; Andrew J Webb; Gwendolyn M Pais; Andrew D Rule; Paul J Jannetto; Marc H Scheetz
Journal:  Crit Care Explor       Date:  2021-06-11

Review 10.  Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury.

Authors:  Seung Hyun Kim; Dean J Naisbitt
Journal:  Allergy Asthma Immunol Res       Date:  2015-07-03       Impact factor: 5.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.